Table 1 Patients characteristics
Variables | Treatment group (n = 33) | Control group (n = 35) | p-value |
|---|---|---|---|
Age, median (range) | 59 (43-75) | 62 (41-78) | 0.74 |
Sex, n | |||
Male | 19 | 20 | |
Female | 14 | 15 | 0.97 |
ECOG PS, median (range) | 0 (0-1) | 0 (0-2) | 0.37 |
Primary tumour location | |||
Right | 11 | 11 | |
Transverse | 1 | 2 | |
Left | 18 | 19 | |
rectum | 3 | 3 | 0.91 |
Metastatic sites | |||
Liver | 24 | 26 | |
Lymph nodes | 7 | 8 | |
Lung | 2 | 1 | 0.98 |
Chemotherapy regimen | |||
Folfiri + cetuximab | 32 | 0 | |
Folfiri | 0 | 33 | |
Folfox + cetuximab | 1 | 0 | 0.94 |
Folfox | 0 | 2 | |
Overall Best Response | |||
CR | 2 | 1 | |
PR | 14 | 15 | |
SD | 6 | 9 | |
PD | 11 | 10 | 0.36 |
Treatment duration | |||
months, median | 4.9 | 5.3 | 0.51 |
PFS | |||
Months, median | 5.7 | 5.4 | 0.52 |